Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Schnell

Showing results (61-70 of 103) with videos related to

Pageof 11
Sort By:
Intensive Care Medicine|February 20, 2019
De-escalation of antimicrobial therapy in critically ill hematology patients: a prospective cohort studyDavid Schnell, Claire Montlahuc, Fabrice Bruneel, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinibTeresa Moran, Ramón Palmero, Mariano Provencio, et al.
Intensive Care Medicine|October 7, 2018
Performance of Doppler-based resistive index and semi-quantitative renal perfusion in predicting persistent AKI: results of a prospective multicenter studyMichael Darmon, Aurelie Bourmaud, Marie Reynaud, et al.
Journal of Critical Care|January 25, 2022
Performance of renal Doppler to predict the occurrence of acute kidney injury in patients without acute kidney injury at admissionDavid Schnell, Aurélie Bourmaud, Marie Reynaud, et al.
Liver Cancer|June 12, 2018
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular CarcinomaChia-Jui Yen, Tae-You Kim, Yin-Hsun Feng, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)Martin Forster, Allan Hackshaw, Tommaso De Pas, et al.
Critical Care (London, England)|April 3, 2026
Amikacin pharmacokinetics after nebulization among intubated patientsNicolas Gregoire, Sandrine Marchand, François Barbier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2013
Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter studyMatthieu Schmidt, Romain Sonneville, David Schnell, et al.
Critical Care Explorations|August 6, 2025
Life-Supporting Treatment Limitations in Patients Who Die Within 48 Hours After ICU Admission: A French, Multicenter, Observational, Exploratory StudyAurélie Nouvel, Pierre Leprovost, Charlotte Larrat, et al.
Intensive Care Medicine|February 8, 2014
Noninvasive mechanical ventilation in acute respiratory failure: trends in use and outcomesDavid Schnell, Jean-François Timsit, Michael Darmon, et al.
Pageof 11

Showing results (61-70 of 103) with videos related to

Sort By:
Pageof 11
Intensive Care Medicine|February 20, 2019
De-escalation of antimicrobial therapy in critically ill hematology patients: a prospective cohort studyDavid Schnell, Claire Montlahuc, Fabrice Bruneel, et al.
Lung Cancer (Amsterdam, Netherlands)|June 20, 2017
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinibTeresa Moran, Ramón Palmero, Mariano Provencio, et al.
Intensive Care Medicine|October 7, 2018
Performance of Doppler-based resistive index and semi-quantitative renal perfusion in predicting persistent AKI: results of a prospective multicenter studyMichael Darmon, Aurelie Bourmaud, Marie Reynaud, et al.
Journal of Critical Care|January 25, 2022
Performance of renal Doppler to predict the occurrence of acute kidney injury in patients without acute kidney injury at admissionDavid Schnell, Aurélie Bourmaud, Marie Reynaud, et al.
Liver Cancer|June 12, 2018
A Phase I/Randomized Phase II Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Nintedanib versus Sorafenib in Asian Patients with Advanced Hepatocellular CarcinomaChia-Jui Yen, Tae-You Kim, Yin-Hsun Feng, et al.
Lung Cancer (Amsterdam, Netherlands)|May 12, 2018
A phase I study of nintedanib combined with cisplatin/gemcitabine as first-line therapy for advanced squamous non-small cell lung cancer (LUME-Lung 3)Martin Forster, Allan Hackshaw, Tommaso De Pas, et al.
Critical Care (London, England)|April 3, 2026
Amikacin pharmacokinetics after nebulization among intubated patientsNicolas Gregoire, Sandrine Marchand, François Barbier, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2013
Clinical features and outcomes in patients with disseminated toxoplasmosis admitted to intensive care: a multicenter studyMatthieu Schmidt, Romain Sonneville, David Schnell, et al.
Critical Care Explorations|August 6, 2025
Life-Supporting Treatment Limitations in Patients Who Die Within 48 Hours After ICU Admission: A French, Multicenter, Observational, Exploratory StudyAurélie Nouvel, Pierre Leprovost, Charlotte Larrat, et al.
Intensive Care Medicine|February 8, 2014
Noninvasive mechanical ventilation in acute respiratory failure: trends in use and outcomesDavid Schnell, Jean-François Timsit, Michael Darmon, et al.
Pageof 11